Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.

A protective effect of angiotensin-converting enzyme (ACE) inhibitors has been shown in patients with diabetic nephropathy but has not been clearly established in nondiabetic renal disease. A multicenter European study was designed to determine whether the ACE inhibitor benazepril was safe and effective in protecting residual renal function in patients with various renal diseases and mild to moderate renal failure. The trial involved 583 patients from 49 centers in Italy, France, and Germany. The patients were randomized to receive benazepril or placebo plus other antihypertensive agents, the target being a diastolic blood pressure of less than 90 mm Hg. Thirty-one patients in the benazepril group and 57 patients in the placebo group reached the end point [the time elapsed from entry to (a) doubling of serum creatinine (SCr) concentrations and (b) start of renal replacement therapy; p < 0.001 at 3 years]. The associated reduction in the relative risk of reaching the end point was 53% in benazepril-treated patients, with actuarial renal survival probability significantly better at 3 years. The best survival of renal function was observed in patients with chronic glomerular diseases and proteinuria greater than 1.0 g/24 h. Benazepril is effective in slowing the rate of progression and improving the survival of renal function in patients with renal diseases of various origins. This protective effect is associated with a clinically relevant decrease in both blood pressure and proteinuria.
AuthorsG Maschio, D Alberti, F Locatelli, J F Mann, M Motolese, C Ponticelli, E Ritz, G Janin, P Zucchelli
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 33 Suppl 1 Pg. S16-20; discussion S41-3 ( 1999) ISSN: 0160-2446 [Print] UNITED STATES
PMID10028949 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Benzazepines
  • Placebos
  • Creatinine
  • benazepril
  • Angiotensin-Converting Enzyme Inhibitors (adverse effects, therapeutic use)
  • Antihypertensive Agents (therapeutic use)
  • Benzazepines (adverse effects, therapeutic use)
  • Blood Pressure (drug effects)
  • Creatinine (blood)
  • Female
  • Humans
  • Kidney Diseases (drug therapy)
  • Male
  • Placebos
  • Prospective Studies
  • Proteinuria (drug therapy)
  • Renal Insufficiency (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: